Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption

被引:2
|
作者
Lau, Chuen-Yen [1 ]
Adan, Matthew A. [1 ]
Earhart, Jessica [1 ]
Seamon, Cassie [2 ]
Nguyen, Thuy [3 ]
Savramis, Ariana [1 ]
Adams, Lindsey [3 ]
Zipparo, Mary-Elizabeth [3 ]
Madeen, Erin [3 ]
Huik, Kristi [3 ]
Grossman, Zehava [3 ]
Chimukangara, Benjamin [2 ]
Wulan, Wahyu Nawang [3 ]
Millo, Corina [4 ]
Nath, Avindra [5 ]
Smith, Bryan R. [5 ]
Ortega-Villa, Ana M. [6 ]
Proschan, Michael [6 ]
Wood, Bradford J. [7 ]
Hammoud, Dima A. [8 ]
Maldarelli, Frank [3 ]
机构
[1] Natl Canc Inst NCI, Natl Inst Hlth NIH, HIV Dynam & Replicat Program, Bethesda, MD 20892 USA
[2] Natl Inst Hlth NIH, Clin Ctr CC, Crit Care Med Dept, Bethesda, MD USA
[3] Natl Canc Inst NCI, Natl Inst Hlth NIH, HIV Dynam & Replicat Program, Frederick, MD USA
[4] Natl Inst Hlth NIH, Clin Ctr CC, PET Dept, Bethesda, MD USA
[5] Natl Inst Neurol Disorders & Stroke NINDS, Natl Inst Hlth NIH, Div Neuroimmunol & Neurovirol, Bethesda, MD USA
[6] Natl Inst Allergy & Infect Dis NIAID, Natl Inst Hlth NIH, Biostat Res Branch, Bethesda, MD USA
[7] Natl Inst Hlth NIH, Clin Ctr CC, Intervent Radiol Radiol & Imaging Sci, Bethesda, MD USA
[8] Natl Inst Hlth NIH, Clin Ctr CC, Radiol & Imaging Sci, Bethesda, MD USA
关键词
HIV; reservoir; treatment interruption; PET/CT; biopsy; clinical trial; HIV persistence; ANTIRETROVIRAL THERAPY; FDG-PET/CT; VIRAL LOAD; SET-POINT; T-CELLS; TOMOGRAPHY; PATIENT; TIME; ADULTS; FUSION;
D O I
10.3389/fmed.2022.979756
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: HIV persistence during antiretroviral therapy (ART) is the principal obstacle to cure. Lymphoid tissue is a compartment for HIV, but mechanisms of persistence during ART and viral rebound when ART is interrupted are inadequately understood. Metabolic activity in lymphoid tissue of patients on long-term ART is relatively low, and increases when ART is stopped. Increases in metabolic activity can be detected by F-18-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and may represent sites of HIV replication or immune activation in response to HIV replication. Methods: FDG-PET imaging will be used to identify areas of high and low metabolic uptake in lymphoid tissue of individuals undergoing long-term ART. Baseline tissue samples will be collected. Participants will then be randomized 1:1 to continue or interrupt ART via analytic treatment interruption (ATI). Image-guided biopsy will be repeated 10 days after ATI initiation. After ART restart criteria are met, image-guided biopsy will be repeated once viral suppression is re-achieved. Participants who continued ART will have a second FDG-PET and biopsies 12-16 weeks after the first. Genetic characteristics of HIV populations in areas of high and low FDG uptake will be assesed. Optional assessments of non-lymphoid anatomic compartments may be performed to evaluate HIV populations in distinct anatomic compartments. Anticipated results: We anticipate that PET standardized uptake values (SUV) will correlate with HIV viral RNA in biopsies of those regions and that lymph nodes with high SUV will have more viral RNA than those with low SUV within a patient. Individuals who undergo ATI are expected to have diverse viral populations upon viral rebound in lymphoid tissue. HIV populations in tissues may initially be phylogenetically diverse after ATI, with emergence of dominant viral species (clone) over time in plasma. Dominant viral species may represent the same HIV population seen before ATI. Discussion: This study will allow us to explore utility of PET for identification of HIV infected cells and determine whether high FDG uptake respresents areas of HIV replication, immune activation or both. We will also characterize HIV infected cell populations in different anatomic locations. The protocol will represent a platform to investigate persistence and agents that may target HIV populations.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Anxiety Symptoms in HIV-Infected Individuals
    Kemppainen, Jeanne K.
    MacKain, Sally
    Reyes, Darcel
    JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2013, 24 (01): : S29 - S39
  • [32] Immunotherapeutic restoration in HIV-infected individuals
    Kim, June Myung
    Han, Sang Hoon
    IMMUNOTHERAPY, 2011, 3 (02) : 247 - 267
  • [33] The use of caspofungin in HIV-infected individuals
    Waters, Laura
    Nelson, Mark
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) : 899 - 908
  • [34] The interruption of outpatient clinical care of HIV-infected patients
    Rodrigues, CS
    Guimaraes, MDC
    Acurcio, FA
    Comini, CC
    REVISTA DE SAUDE PUBLICA, 2003, 37 (02): : 183 - 190
  • [35] Health Literacy: Impact on the Health of HIV-Infected Individuals
    Wawrzyniak, Andrew J.
    Ownby, Raymond L.
    Mccoy, Katryna
    Waldrop-Valverde, Drenna
    CURRENT HIV/AIDS REPORTS, 2013, 10 (04) : 295 - 304
  • [36] Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics
    Tarr, Philip E.
    Rotger, Margalida
    Telenti, Amalio
    PHARMACOGENOMICS, 2010, 11 (04) : 587 - 594
  • [37] Immune resilience in HIV-infected individuals seronegative for cytomegalovirus
    Barrett, Lisa
    Stapleton, Staci N.
    Fudge, Neva J.
    Grant, Michael D.
    AIDS, 2014, 28 (14) : 2045 - 2049
  • [38] Correlates of Unstructured Antiretroviral Treatment Interruption in a Cohort of HIV-Positive Individuals in British Columbia
    Samji, Hasina
    Chen, Yalin
    Salters, Kate
    Montaner, Julio S. G.
    Hogg, Robert S.
    AIDS AND BEHAVIOR, 2014, 18 (11) : 2240 - 2248
  • [39] Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption
    Kenneth H Huang
    Mona R Loutfy
    Christos M Tsoukas
    Nicole F Bernard
    BMC Infectious Diseases, 8
  • [40] High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals
    Li, M.
    Foli, Y.
    Liu, Z.
    Wang, G.
    Hu, Y.
    Lu, Q.
    Selvaraj, S.
    Lam, W.
    Paintsil, E.
    HIV MEDICINE, 2017, 18 (01) : 45 - 55